Results 91 to 100 of about 62,487 (100)
Some of the next articles are maybe not open access.

KEYNOTE-811 pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction cancer (mG/GEJC): A double-blind, randomized, placebo-controlled phase 3 study.

Journal of Clinical Oncology, 2019
TPS4146 Background: Combination therapy with the anti-HER2 antibody trastuzumab with fluoropyrimidine and platinum is the current standard for patients with HER2+ mG/GEJc.
Y. Janjigian   +12 more
semanticscholar   +1 more source

Trajectories of Suicidal Ideation During 12 Weeks of Escitalopram or Nortriptyline Antidepressant Treatment Among 811 Patients With Major Depressive Disorder.

Journal of Clinical Psychiatry, 2019
BACKGROUND Suicidal ideation is a frequent and difficult-to-treat clinical challenge among patients with major depressive disorder (MDD). However, little is known regarding the differential development during antidepressant treatment and whether some ...
T. Madsen   +14 more
semanticscholar   +1 more source

KEYNOTE-811 pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction cancer (mG/GEJc): A double-blind, randomized, placebo-controlled phase III study.

, 2019
TPS4146Background: Combination therapy with the anti-HER2 antibody trastuzumab with fluoropyrimidine and platinum is the current standard for patients with HER2+ mG/GEJc.
H. Chung   +13 more
semanticscholar   +1 more source

KEYNOTE-811: pembrolizumab in advanced HER2+ gastric cancer

Nature reviews: Gastroenterology & hepatology, 2022
J. Hindson
semanticscholar   +1 more source

LBA-4 Initial data from the phase 3 KEYNOTE-811 study of trastuzumab and chemotherapy with or without pembrolizumab for HER2-positive metastatic gastric or gastroesophageal junction (G/GEJ) cancer

Annals of Oncology, 2021
Y. Janjigian   +18 more
semanticscholar   +1 more source

Global age-sex-specific mortality, life expectancy, and population estimates in 204 countries and territories and 811 subnational locations, 1950–2021, and the impact of the COVID-19 pandemic: a comprehensive demographic analysis for the Global Burden of Disease Study 2021

The Lancet
Austin E. Schumacher   +499 more
semanticscholar   +1 more source

1400O Final overall survival for the phase III, KEYNOTE-811 study of pembrolizumab plus trastuzumab and chemotherapy for HER2+ advanced, unresectable or metastatic G/GEJ adenocarcinoma

Annals of Oncology
Y. Janjigian   +19 more
semanticscholar   +1 more source

128MO Final overall survival for the phase III, KEYNOTE-811 study of pembrolizumab plus trastuzumab and chemotherapy for HER2+ advanced, unresectable or metastatic G/GEJ adenocarcinoma

Annals of Oncology
S. Rha   +19 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy